SCPH
Income statement / Annual
Last year (2024), scPharmaceuticals Inc.'s total revenue was $36.33 M,
an increase of 167.28% from the previous year.
In 2024, scPharmaceuticals Inc.'s net income was -$85.15 M.
See scPharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$36.33 M |
$13.59 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$11.36 M
|
$3.81 M
|
$468.00 K
|
$438.00 K
|
$399.00 K
|
$364.00 K
|
$332.00 K
|
$167.00 K
|
$5.00 K
|
$4.00 K
|
| Gross Profit |
$24.97 M
|
$9.78 M
|
-$468.00 K
|
-$438.00 K
|
-$399.00 K
|
-$364.00 K
|
-$332.00 K
|
-$167.00 K
|
-$5.00 K
|
-$4.00 K
|
| Gross Profit Ratio |
0.69
|
0.72
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.10 M
|
$11.81 M
|
$15.53 M
|
$16.04 M
|
$18.15 M
|
$24.63 M
|
$15.95 M
|
$14.33 M
|
$11.86 M
|
$8.27 M
|
| General & Administrative Expenses |
$0.00
|
$53.37 M
|
$20.62 M
|
$9.78 M
|
$11.78 M
|
$8.27 M
|
$13.72 M
|
$9.11 M
|
$6.05 M
|
$2.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$77.65 M
|
$53.37 M
|
$20.62 M
|
$9.78 M
|
$11.78 M
|
$8.27 M
|
$13.72 M
|
$9.11 M
|
$6.05 M
|
$2.58 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$56.00 K
|
$75.00 K
|
$38.00 K
|
-$68.00 K
|
| Operating Expenses |
$89.75 M
|
$65.18 M
|
$36.16 M
|
$25.82 M
|
$29.93 M
|
$32.91 M
|
$29.67 M
|
$23.44 M
|
$17.91 M
|
$10.84 M
|
| Cost And Expenses |
$101.11 M
|
$68.99 M
|
$36.16 M
|
$25.82 M
|
$29.93 M
|
$32.91 M
|
$29.67 M
|
$23.44 M
|
$17.91 M
|
$10.84 M
|
| Interest Income |
$3.44 M
|
$5.10 M
|
$1.20 M
|
$49.00 K
|
$315.00 K
|
$1.66 M
|
$1.71 M
|
$341.00 K
|
$7.00 K
|
$0.00
|
| Interest Expense |
$7.57 M
|
$8.12 M
|
$3.30 M
|
$2.58 M
|
$2.59 M
|
$1.77 M
|
$1.43 M
|
$797.00 K
|
$6.51 M
|
$0.00
|
| Depreciation & Amortization |
$148.00 K
|
$626.00 K
|
$468.00 K
|
$438.00 K
|
$399.00 K
|
$364.00 K
|
$332.00 K
|
$167.00 K
|
$5.00 K
|
$4.00 K
|
| EBITDA |
-$77.43 M |
-$46.06 M |
-$33.07 M |
-$25.02 M |
-$29.22 M |
-$30.87 M |
-$27.68 M |
-$25.15 M |
-$17.86 M |
-$10.84 M |
| EBITDA Ratio |
-2.13
|
-3.39
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.78
|
-4.08
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$20.37 M
|
$586.00 K
|
-$681.00 K
|
-$2.21 M
|
-$2.28 M
|
-$91.00 K
|
$224.00 K
|
-$381.00 K
|
-$6.47 M
|
$326.00 K
|
| Income Before Tax |
-$85.15 M
|
-$54.81 M
|
-$36.84 M
|
-$28.03 M
|
-$32.21 M
|
-$33.00 M
|
-$29.44 M
|
-$23.82 M
|
-$24.38 M
|
-$10.52 M
|
| Income Before Tax Ratio |
-2.34
|
-4.03
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$224.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$85.15 M
|
-$54.81 M
|
-$36.84 M
|
-$28.03 M
|
-$32.21 M
|
-$34.42 M
|
-$29.44 M
|
-$23.82 M
|
-$24.38 M
|
-$10.52 M
|
| Net Income Ratio |
-2.34
|
-4.03
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.91 |
-1.42 |
-1.3 |
-1.02 |
-1.31 |
-1.85 |
-1.59 |
-8.04 |
-2.18 |
-0.94 |
| EPS Diluted |
-1.91 |
-1.42 |
-1.3 |
-1.02 |
-1.31 |
-1.85 |
-1.59 |
-8.04 |
-2.18 |
-0.94 |
| Weighted Average Shares Out |
$44.52 M
|
$38.51 M
|
$28.36 M
|
$27.35 M
|
$24.57 M
|
$18.60 M
|
$18.56 M
|
$2.96 M
|
$11.20 M
|
$11.20 M
|
| Weighted Average Shares Out Diluted |
$44.52 M
|
$38.51 M
|
$28.36 M
|
$27.35 M
|
$24.57 M
|
$18.60 M
|
$18.56 M
|
$2.96 M
|
$11.20 M
|
$11.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
